TScan Therapeutics Ratios (2020-2026) | TCRX

Ratios Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
EBT Margin (Quarter)
-1,155.51%-1,048.55%-571.83%-534.79%-372.21%-483.05%-631.57%-389.02%-763.82%-591.64%-350.21%-5,325.44%-5,906.90%-2,849.09%-7,027.52%-1,703.55%-1,201.30%-1,422.14%-1,253.84%-2,919.14%
EBIT Margin (Quarter)
-374.96%-656.80%-497.62%-535.02%-375.89%-492.95%-602.55%-392.12%-781.77%-636.69%-296.17%-5,542.93%-6,364.55%-3,109.82%-5,520.60%-1,669.74%-1,256.60%-1,475.59%-929.41%-2,967.31%
EBITDA Margin (Quarter)
-374.96%-656.80%-497.62%-535.02%-375.89%-492.95%-602.55%-392.12%-781.77%-636.69%-296.17%-5,542.93%-6,364.55%-3,109.82%-5,520.60%-1,669.74%-1,256.60%-1,475.59%-929.41%-2,967.31%
Operating Margin (Quarter)
-374.96%-656.80%-497.62%-535.02%-375.89%-492.95%-602.55%-392.12%-781.77%-636.69%-296.17%-5,542.93%-6,364.55%-3,109.82%-5,520.60%-1,669.74%-1,256.60%-1,475.59%-929.41%-2,967.31%
Net Margin (Quarter)
-1,155.51%-1,048.55%-571.83%-534.79%-372.21%-483.05%-631.57%-389.02%-763.82%-591.64%-350.21%-5,325.44%-5,906.90%-2,849.09%-7,027.52%-1,703.55%-1,201.30%-1,422.14%-1,253.84%-2,919.14%
FCF Margin (Quarter)
-324.51%-870.27%-581.32%-683.71%-376.23%-450.49%-513.15%-407.09%-701.56%199.67%-329.00%-5,295.41%-5,053.54%-2,791.99%-4,255.64%-1,801.84%-1,061.87%-1,257.98%-1,244.92%-2,479.53%
Efficiency
Assets Average (Quarter)
167.45M196.50M178.16M160.31M158.93M182.27M186.33M245.25M304.15M281.76M256.49M307.85M361.45M359.57M351.91M315.63M280.39M245.51M215.39M
Invested Capital (Quarter)
1.11M3.35M6.80M10.34M
Asset Utilization Ratio (Quarter)
0.050.050.060.080.080.070.090.060.050.070.060.040.030.010.010.020.030.040.04
Leverage & Solvency
Interest Coverage Ratio (Quarter)
-0.48-1.68-6.70-82.48-10.37-23.79-25.40-25.20-3.29-32.71-35.83-34.05-46.83-53.39-56.10-53.01-22.85-42.29
Debt Ratio (Quarter)
0.180.150.170.090.100.110.130.080.090.090.100.110.120.140.16
Times Interest Earned (Quarter)
-0.48-1.68-6.70-82.48-10.37-23.79-25.40-25.20-3.29-32.71-35.83-34.05-46.83-53.39-56.10-53.01-22.85-42.29
Valuation
Enterprise Value (Quarter)
-106.20M-182.31M-161.41M-140.84M-125.60M-137.31M-120.03M-95.61M-208.84M-215.42M-192.04M-162.78M-297.68M-271.12M-290.11M-251.69M-218.04M-184.45M-152.41M-128.06M
Return Ratios
Return on Sales (Quarter)
-0.12%-0.10%-0.06%-0.05%-0.04%-0.05%-0.06%-0.04%-0.08%-0.06%-0.04%-0.53%-0.59%-0.28%-0.70%-0.17%-0.12%-0.14%-0.13%-0.29%
Return on Capital Employed (Quarter)
-29.24%-27.77%-35.62%-42.93%-43.69%-40.39%-42.50%-39.30%-33.49%-37.09%-45.37%-41.44%-35.90%-41.66%-43.37%-50.73%-59.19%-59.88%-65.86%
Return on Assets (Quarter)
0.00%0.00%-0.01%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-0.01%-0.01%-0.01%